Current Affairs - Science - Discussion

Phesgo is a subcutaneous treatment that combines two monoclonal antibodies—trastuzumab and pertuzumab—into a single under-the-skin injection. It significantly reduces hospital time from around 2.5 hours to just 5–8 minutes while maintaining the same safety and efficacy as intravenous therapy. Designed for HER2-positive breast cancer, which accounts for about 20–25% of all breast cancer cases, Phesgo represents a major advancement in making cancer care more convenient, patient-centered, and efficient by simplifying the treatment process without compromising medical outcomes.